Replies to post #660783 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

No. In the cancer Merck treats best, melanoma, the percent decrease in likelihood of recurrence or death, with the added Moderna vaccine, decreased by at most, 49% in a phase 2 trial.

Whereas for DCVax-l, the increased chance for life at three years was much higher, and kept increasing over time.